NAV30/05/2024 Var.+7.4801 Type of yield Focus sugli investimenti Società d'investimento
1,154.1700USD +0.65% reinvestment Equity Worldwide Fuchs Asset M. 

Investment strategy

The main objective of the Fund is to seek to maximise total return. The Fund invests globally with at least 85% of its total assets in the equity securities of companies whose predominant economic activity is in the pharmaceuticals, biotechnology and life science sectors. The overall investment strategy of the BlueBox Precision Medicine Fund is to seek out companies that will create value for the Shareholders from precision medicine: the multi-year trend of increasingly precise and targeted drug development in the pharmaceutical and biotechnology industries. The BlueBox Precision Medicine Fund will typically hold 25 to 45 positions. The holding periods are expected to be generally long (multiple years) and turnover low, although at times the BlueBox Precision Medicine Fund may utilise shorter holding periods if value is realised more quickly or unexpected events occur.
 

Investment goal

The main objective of the Fund is to seek to maximise total return.
 

Dati master

Type of yield: reinvestment
Fondi Categoria: Equity
Region: Worldwide
Settore: Sector Health / Pharma
Benchmark: -
Business year start: 01/01
Ultima distribuzione: -
Banca depositaria: Northern Trust Global Services SE
Domicilio del fondo: Luxembourg
Permesso di distribuzione: Germany, Switzerland
Gestore del fondo: Mark Dainty
Volume del fondo: 14.93 mill.  USD
Data di lancio: 01/03/2023
Investment focus: -

Condizioni

Sovrapprezzo emissione: 5.00%
Tassa amministrativa massima: 1.00%
Investimento minimo: 100,000.00 USD
Deposit fees: -
Redemption charge: 0.00%
Prospetto semplificato: -
 

Società d'investimento

Funds company: Fuchs Asset M.
Indirizzo: 49,boulevard Prince Henri, 1724, Luxembourg
Paese: Luxembourg
Internet: info@fuchsgroup.com
 

Attività

Stocks
 
98.20%
Cash and Other Assets
 
1.80%

Paesi

United States of America
 
72.40%
United Kingdom
 
6.00%
Belgium
 
5.90%
France
 
5.30%
Switzerland
 
3.10%
Italy
 
3.00%
Denmark
 
2.50%
Altri
 
1.80%

Filiali

Pharma/Biotechnology
 
64.90%
Pharma, production
 
3.00%
Cash / other assets
 
1.80%
Altri
 
30.30%